Join
Live feed
·
PRReleasevia Quantisnow
AnaptysBio Inc. logo
Vanda Pharmaceuticals Inc. logo

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ByQuantisnow·Wall Street's wire, on your screen.
ANAB· AnaptysBio Inc.VNDA· Vanda Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANAB (AnaptysBio Inc.), VNDA (Vanda Pharmaceuticals Inc.) and more on Quantisnow.

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis | Quantisnow